What Stemetil (Chlorpromazine) Treats: Main Uses and Benefits

Chlorpromazine is commonly used across domains where additional symptomatic support is needed.

Stabilization and Symptom Relief

Chlorpromazine is used for managing the pronounced manifestations of psychotic disorders, including schizophrenia and the manic phase of bipolar illness. It is also applied in addressing specific, severe somatic symptoms, notably persistent nausea and vomiting and intractable hiccups (singultus), and is relevant for easing acute excitement or preoperative apprehension. The medication provides support that helps ease the overall symptom burden and may assist with maintaining functional stability during disruptive episodes. It is considered relevant in situations where symptoms may become intense or disruptive. This offers symptomatic relief that supports patients during episodes of heightened discomfort across various clinical contexts.

---

Quick Fact: Relief for Severe Somatic Symptoms	Symptom Type	Application
Gastrointestinal	Persistent, severe nausea and vomiting
Physical Reflex	Intractable hiccups (singultus)
Acute Agitation	Severe restlessness and apprehension

Who Can and Cannot Use Stemetil (Chlorpromazine)?

The eligibility for Chlorpromazine use is strictly defined by regulatory documents, distinguishing between approved populations, restricted use, and absolute contraindications.

Populations with Absolute Contraindications

Use is prohibited for patients with a known phenothiazine hypersensitivity, those in a comatose state, or those experiencing severe Central Nervous System (CNS) depression. Absolute non-eligibility also applies to individuals with bone marrow depression, phaeochromocytoma, or circulatory collapse. The medicine is also contraindicated when administered concurrently with certain drugs, such as Levodopa.

Age and Condition Restrictions

Population Group	Regulatory Status
Elderly patients with dementia-related psychosis	Contraindicated (mandated warning due to increased mortality risk)
Children under 6 months of age	Not Recommended (safety and efficacy not established)
Pregnant or Breastfeeding Patients	Not Recommended (due to potential risk to the infant)

Use requires caution in patients with a history of seizures/epilepsy, as the drug may lower the seizure threshold. Patients with severe hepatic or renal impairment may also require restricted use due to the risk of drug accumulation.

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Chlorpromazine, primarily falling into pharmacokinetic and pharmacodynamic categories. Co-administration with certain substances is strictly contraindicated due to the risk of severe adverse outcomes as documented by health authorities.

Formally Documented Contraindicated Combinations

Substance Category	Interaction Outcome (Regulatory Description)
QTc-Prolonging Drugs (e.g., Sotalol, Amiodarone)	Increased risk of serious ventricular arrhythmias (e.g., Torsade de Pointes).
CNS Depressants (e.g., high doses of alcohol, barbiturates)	Risk of profound, additive central nervous system depression or comatose states.
Metrizamide	Risk of seizure; necessitates discontinuation of Chlorpromazine 24 hours prior to administration.

Pharmacokinetic and Pharmacodynamic Interaction Patterns

Co-administration with strong CYP2D6 inhibitors (e.g., Fluoxetine, Paroxetine) reduces Chlorpromazine clearance, leading to increased exposure and higher plasma concentrations. Conversely, chronic treatment with Barbiturates may significantly increase Chlorpromazine clearance. The regulatory profile also documents antagonism when Chlorpromazine is used with Levodopa or other Dopaminergic Agonists.

Administration Timing and Non-Medicinal Substances

Certain substances interfere with absorption. Antacids must be separated by at least two hours after Chlorpromazine administration to prevent impaired absorption. Consumption of Alcohol must be strictly avoided as it potentiates the sedative effects and increases the risk of hypotension, as noted in official prescribing information. Beverages like Tea and Coffee are also documented to potentially prevent the absorption of oral Chlorpromazine.

How Stemetil (Chlorpromazine) Works

Chlorpromazine’s action stems from a pleiotropic antagonism, simultaneously blocking several types of neurotransmitter receptors to modulate central and peripheral signaling pathways.

Central Dopaminergic Signaling Modulation

This mechanism centers on the drug's role as an antagonist (blocker) at the Dopamine D2 receptor ( D2) throughout the central nervous system ( CNS). By occupying this primary target, Chlorpromazine directly interferes with hyperactive dopaminergic signaling in key brain circuits. This action modifies the flow of neurochemical signals in processes governing emotional response and perception.

Interruption of the Emesis Control Pathway

The antiemetic action is achieved by the targeted blockade of D2 receptors specifically located in the Chemoreceptor Trigger Zone ( CTZ) of the brainstem. This molecular interference prevents the CTZ from detecting and transmitting chemical signals that initiate the vomiting reflex arc, resulting in the disruption of the physiological impulse for emesis.

Systemic Influence via Alpha1 and Histamine Blockade

Chlorpromazine’s non-selective action extends to blocking Histamine H1 receptors ( H1) centrally and Alpha1 Adrenergic receptors (alpha1) peripherally. H1 antagonism contributes to attenuation of central histaminergic signaling, while alpha1 blockade disrupts the signaling that causes blood vessel constriction, leading to a physiological lowering of peripheral vascular resistance.

Chlorpromazine is administered through several approved routes, depending on the clinical context: oral (tablets or solution) for routine and maintenance therapy, intramuscular (IM) injection for the prompt control of severe symptoms, and intravenous (IV) infusion for strictly defined conditions like intractable hiccups.

Treatment initiation begins with a low starting dose which is then gradually increased (titrated) until the effective dosage is established, which may take weeks or months. For chronic conditions, the total daily dose is often divided and taken two to four times throughout the day. Once symptoms are controlled, the optimal dose is maintained for a period, after which a gradual reduction (tapering) to the lowest effective level is attempted.

Population Group	Labeled Administration Rule (Example Range)
Older Adults	Start with one-third to one-half the usual adult starting dose; increase dosage more gradually.
Pediatric (6 months+)	Dosing is typically weight-based (e.g., 0.5 to 1 mg/kg per dose), with specific daily maximums; use is not established below 6 months.

For parenteral administration, IM injections must be administered slowly and deeply into the muscle. IV administration requires the drug to be diluted with 0.9% sodium chloride solution to a concentration generally not exceeding 1 mg/mL and administered as a slow infusion. Following any parenteral dose, the patient is required to remain lying down for at least thirty minutes.

Stemetil (Prochlorperazine): Recent Clinical Evidence

Stemetil is a brand name for the active ingredient prochlorperazine, which is classified as a phenothiazine antipsychotic. While historically used for psychiatric disorders, its primary current clinical use is centered on its strong antiemetic (anti-nausea and anti-vomiting) and anti-vertigo properties.

Core Indications and Evidence

Authoritative clinical sources confirm the use of prochlorperazine for several specific conditions, primarily due to its effect on the chemoreceptor trigger zone in the brain.

Indication Focus	Type of Evidence	Summary of Findings
Severe Nausea and Vomiting	Established Clinical Use	Consistently used to control severe, difficult-to-manage nausea and emesis, including that associated with chemotherapy and post-operative recovery.
Vertigo and Dizziness	Established Clinical Use	Used for managing vertigo associated with inner ear disorders, such as Ménière's syndrome and labyrinthitis.
Schizophrenia and Psychosis	Systematic Reviews	Comparative reviews suggest its effectiveness for reducing symptoms in some individuals with psychosis, though it may be associated with a higher incidence of specific side effects, such as sedation and movement disorders, compared to some newer agents.

Current Research Focus

Recent investigations have focused on evaluating potential new applications for the drug (repurposing) and comparing its long-term tolerability against modern treatments. Ongoing clinical trials are exploring the effects of prochlorperazine in diverse areas, including its use as an adjunctive treatment for certain cancers and viral infections, though these remain investigational and are not approved uses.

Common questions about Stemetil (Chlorpromazine) (FAQ)

---

Q: Can Stemetil (Chlorpromazine) cause long-term eye problems or changes in vision?

Official documents indicate that long-term therapy, particularly at higher doses, has been associated with changes in ocular tissues, such as the lens and cornea. These changes may lead to issues like photophobia (increased sensitivity to light) and other vision changes.

---

Q: What are the common side effects that usually improve after the first few weeks of taking Stemetil (Chlorpromazine)?

According to official product information, drowsiness is a very common side effect that is typically mild and may disappear after the first one or two weeks of treatment. Other initial effects, such as certain movement disorders known as Extrapyramidal Symptoms (EPS), may also be more likely to occur at the start of therapy.

---

Q: How does Stemetil (Chlorpromazine) affect the body's ability to regulate temperature?

Official product information describes that Chlorpromazine can affect the part of the brain that regulates body temperature. This physiological effect may make an individual more sensitive to exposure to extreme heat or cold.

---

Q: Can Stemetil (Chlorpromazine) cause increased sensitivity to the sun or skin reactions?

Regulatory documents confirm that Chlorpromazine is associated with increased photosensitivity (making skin more sensitive to the sun) and other skin reactions. The official prescribing information advises that protective measures against sun exposure may be needed due to this risk.

---

Q: Does Stemetil (Chlorpromazine) cause sexual side effects for men or women?

Official documents state that sexual dysfunction and impotence are documented as possible side effects. Other related endocrine changes, such as changes in the menstrual cycle or breast discharge (galactorrhea), due to elevated prolactin levels are also noted.

---

Q: Is it possible for Stemetil (Chlorpromazine) to cause a change in skin color over time?

Yes, according to official documents, long-term use of Chlorpromazine has been reported to cause changes in skin pigmentation. This change is typically described as a tan or a blue-gray discoloration.

---

Q: How does Stemetil (Chlorpromazine) affect blood sugar levels according to official information?

Official product information states that the use of this medication can be associated with high blood sugar, a condition known as hyperglycemia. In some rare cases, this metabolic effect has been linked to severe complications.

---

Q: How might Stemetil (Chlorpromazine) affect a person’s ability to drive or operate machinery?

Regulatory documents warn that this medication can cause drowsiness and may impair mental or physical abilities required for skilled tasks. The official product information recommends caution regarding operating complex equipment, including driving, due to these potential effects.

---

Q: Can nicotine or smoking affect how Stemetil (Chlorpromazine) works in the body?

Studies and official information indicate that smoking can affect the rate at which the body clears the medicine from the system. Official information indicates that this potential effect on clearance may be a factor when determining an appropriate dosage.

---

Q: Does Stemetil (Chlorpromazine) interact with birth control pills or other forms of hormonal contraception?

Official interaction documents suggest that co-administration with estrogens, which are commonly found in hormonal contraceptives, may increase the effects and blood levels of Chlorpromazine. This potential interaction may be a factor requiring careful management.

---

Q: How long does Stemetil (Chlorpromazine) stay in the body after the last dose is taken?

The time it takes for the amount of Chlorpromazine in the body to be reduced by half (the half-life) is reported to average between 23 and 37 hours. This lengthy half-life means the medicine may remain in the body for a significant period after the last dose.

---

Q: What are the potential withdrawal symptoms described in official documents if Stemetil (Chlorpromazine) is stopped suddenly?

Regulatory documents confirm that if the medication is stopped suddenly after a long period of use, certain withdrawal symptoms may occur. These can include physical symptoms like gastritis, nausea, vomiting, dizziness, and tremors. The official guidance states that a gradual reduction of dosage may be attempted to help minimize the chance of these effects.

---

Q: Are people with Parkinson's disease generally advised against using Stemetil (Chlorpromazine)?

According to official documents, the use of Chlorpromazine requires caution in patients with Parkinson's disease. The medicine is documented to potentially counteract the therapeutic effects of Levodopa and related medications used to manage Parkinson’s symptoms.

---

Q: Is there an antidote mentioned in official sources for a Stemetil (Chlorpromazine) overdose?

Official overdose treatment guidelines state that there is no single, specific antidote for Chlorpromazine overdose. Official guidelines note that the clinical management for an overdose is generally supportive and aimed at addressing specific symptoms.

---

Q: Is Stemetil (Chlorpromazine) known to affect fertility in men or women?

Official information indicates that antipsychotics, including Chlorpromazine, can cause increased prolactin levels, a condition known as hyperprolactinemia. This hormonal change is cited as a potential cause of effects such as menstrual irregularities or infertility.

---

Q: What type of eye examinations might be recommended during long-term treatment with Stemetil (Chlorpromazine)?

Due to the potential for deposits to form in the eye tissues, the official prescribing information includes a recommendation for annual slit-lamp eye examinations during long-term therapy, particularly at higher doses.

---

Q: Is it true that Stemetil (Chlorpromazine) can be used before a surgical procedure for relaxation?

Yes, the official indications for Chlorpromazine include its use for the relief of restlessness and apprehension before surgery. This labeled use allows the medication to be administered as a preoperative agent.

---

Q: Why is Stemetil (Chlorpromazine) sometimes called a 'low-potency' antipsychotic?

Chlorpromazine is often described as a low-potency typical antipsychotic, a term that refers to its general pharmacological profile. Official documents describe this profile as having fewer movement side effects (EPS) but more common effects like sedation and dry mouth.

---

Q: How does Stemetil (Chlorpromazine) affect the body's prolactin hormone levels?

Official documents confirm that Chlorpromazine can cause elevated levels of the hormone prolactin, a condition called hyperprolactinemia. This hormonal change may be associated with various endocrine and sexual side effects.

---

Q: Does Stemetil (Chlorpromazine) contain lactose or other ingredients that might be problematic for allergies?

Yes, according to the official description, the tablet formulation of Chlorpromazine contains lactose monohydrate as an inactive ingredient (excipient), along with other non-active components.

---

Q: Can Stemetil (Chlorpromazine) be used to treat symptoms of acute intermittent porphyria?

Yes, one of the labeled uses for Chlorpromazine is specifically for the treatment of symptoms associated with acute intermittent porphyria.

Official Storage and Disposal Requirements

Storage and handling of Chlorpromazine must strictly follow the requirements defined by regulatory labeling to maintain product stability and safety.

Storage Conditions

The medication must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from light, as prolonged exposure may cause the crystalline powder to darken. Regulatory instructions also require that the tablets be stored in a tight container.

Safety and Disposal

Chlorpromazine must be kept out of the reach of children.

Disposal of any unused or expired product must be executed according to local regulations.